Interleukin‐21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma
Interleukin‐21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma
复制标题
DOI：
10.1002/jgm.817
复制
发表时间：
2006-01
期刊：
影响因子：
--
通讯作者：
H. Nakano;T. Kishida;H. Asada;M. Shin-Ya;T. Shinomiya;J. Imanishi;Taketoshi Shimada;S. Nakai;M. Takeuchi;Y. Hisa;O. Mazda
中科院分区：
文献类型：
--
作者：
H. Nakano;T. Kishida;H. Asada;M. Shin-Ya;T. Shinomiya;J. Imanishi;Taketoshi Shimada;S. Nakai;M. Takeuchi;Y. Hisa;O. Mazda
白细胞介素-21（IL-21）在T、B和自然杀伤（NK）细胞的调节中起重要作用。我们推测，细胞因子可能通过刺激Th 1和Th 2免疫应答为癌症提供一种新的免疫治疗策略。在这种情况下，在患有皮下头颈鳞状细胞癌（HNSCC）的小鼠中检查了IL-21诱导的抗肿瘤免疫力。
Interleukin‐21 (IL‐21) plays important roles in the regulation of T, B, and natural killer (NK) cells. We hypothesized that the cytokine may provide a novel immunotherapy strategy for cancer by stimulating both Th1 and Th2 immune responses. In this context, antitumor immunity induced by IL‐21 was examined in mice bearing subcutaneous head and neck squamous cell carcinomas (HNSCC).